InMed’s CEO, Eric A. Adams, will join Robert Sassoon of Water Tower Research for a Fireside Chat.
Join the meeting where they’ll discuss:
- InMed’s rare cannabinoid pharmaceutical programs in Epidermolysis Bullosa, Glaucoma and Neurodegenerative diseases
- Bioidentical rare cannabinoid sales by BayMedica, InMed’s subsidiary
- Upcoming catalysts